en.wikipedia.org website review
Improve your SEO :: free trial!
en.wikipedia.org is 44% geoptimaliseerd!
SEO Keyword summary for en.wikipedia.org/wiki/list_of_antineoplastic_agents
Keywords are extracted from the main content of your website and are the primary indicator of the words this page could rank for. By frequenty count we expect your focus keyword to be rare
Focus keyword
Short and long tail
Short Tail Keywords rare cancer uncommon |
long Tail Keywords (2 words) syndrome rare myeloid leukaemia peripheral neuropathy lung cancer alkylates dna |
long Tail Keywords (3 words) acute myeloid leukaemia cell lung cancer non-small cell lung acute lymphoblastic leukaemia stevensjohnson syndrome rare toxic epidermal necrolysis chronic myeloid leukaemia |
en.wikipedia.org On-Page SEO Scan
Descriptive Elements
The <head> element of a en.wikipedia.org/wiki/list_of_antineoplastic_agents page is used to inform the browser and visitors of the page about the general meta information. The head section of the page is where we place the page title, the definition of the HTML version used, the language of in which the page is written. In the head section we can also include JavaScript and CSS (markup) files for the page.
Page title
Title length
list antineoplastic agents wikipedia
Meta description
Meta description legth
Meta description SEO
No meta relevance in the description detected !
Content SEO
Number of Words
Spam detected?
Headings
Heading distribution
Heading normalisation
Heading SEO impact
Emphasis (bold and italic)
Emphasis SEO impact
Images
Number of images
Images dimensions
Image alt descriptions
Images SEO impact
wikipedia free encyclopedia wikimedia foundation powered mediawiki
Mobile SEO en.wikipedia.org/wiki/list_of_antineoplastic_agents
Mobile rendering
Mobile optimizations
Responsive design detected (mobile css)
No flash detected !
Mobile improvement
Marketing / lead generation for en.wikipedia.org/wiki/list_of_antineoplastic_agents
Social Media
Facebook shares | Facebook likes | ||
Facebook comments | Tweets | ||
Google +1 |
Conversion form
Search form
Analytics
Online presence
SERP Preview
SERP Title
SERP Link
SERP Description
Domain Level SEO
Domain name
16 characters long
Domain name SEO Impact
Path name
No contextual keywords found in path
Structured data
Publisher Markup
Other Structured data
Website configuration
Correct processing of non-existing pages?
Favicon icon found?
Robots.txt found?
Sitemap found?
Navigation and internal links
Navigation
Url seperator
Human readable urls
Number of links
Link SEO Impact
statistics
|
en.m.wikipedia.org |
en.wikipedia.org wikimedia foundation inc
|
w httpsenwikipediaorgwindexphptitlelistofantineoplasticagentsoldid1242355862
page information
printable version
sitimagene ceradenovec
|
wiki chemotherapeutic agents
antineoplastic agents
cancer
azacitidine
dna methyltransferase
myelodysplastic syndromes
acute myeloid leukaemia
chronic myeloid leukaemia
myelosuppression
kidney failure
renal tubular acidosis
hypokalaemia
capecitabine
fluorouracil
breast cancer
colorectal cancer
stomach cancer
oesophageal
hypertriglyceridaemia
carmofur
cladribine
hairy cell leukaemia
chronic lymphocytic leukaemia
haemolytic anaemia
stevensjohnson syndrome
toxic epidermal necrolysis
clofarabine
ribonucleotide reductase
dna polymerase
acute lymphoblastic leukaemia
cytokine release syndrome
pancreatitis
cytarabine
lymphomas
progressive multifocal leucoencephalopathy
anaphylaxis
pericarditis
conjunctivitis
peripheral neuropathy
decitabine
sickle cell anaemia
thrombocythaemia
floxuridine
fludarabine
nonhodgkin lymphoma
waldenstrom macroglobulinaemia
hyperglycaemia
pneumonitis
haemorrhagic cystitis
thymidylate synthase
anal
gastric cancer
head and neck
pancreatic cancer
bowens disease
actinic keratoses
gemcitabine
bladder
nasopharyngeal
nonsmall cell lung
ovarian cancer
inflammatory bowel disease
haemolytic uraemic syndrome
thrombotic thrombocytopenic purpura
myocardial infarction
mercaptopurine
acute promyelocytic leukaemia
lymphoblastic lymphoma
nelarabine
guillainbarr syndrome
pentostatin
adenosine deaminase
tegafur
thymidylate
tioguanine
methotrexate
dihydrofolate reductase
osteosarcoma
graftversushost disease
systemic sclerosis
osteoporosis
macrocytic anaemia
pemetrexed
glycinamide ribonucleotide formyltransferase
malignant mesothelioma
supraventricular tachycardia
pralatrexate
raltitrexed
trimetrexate
hydroxycarbamide
essential thrombocytosis
polycythaemia vera
myelofibrosis
irinotecan
topoisomerase i
topotecan
daunorubicin
topoisomerase ii
myelodysplastic syndrome
doxorubicin
wilms tumour
kaposis sarcoma
neuroblastoma
multiple myeloma
epirubicin
idarubicin
mitoxantrone
prostate cancer
multiple sclerosis
valrubicin
etoposide
teniposide
cabazitaxel
docetaxel
paclitaxel
endometrial cancer
vinblastine
vincristine
vindesine
vinflunine
vinorelbine
altretamine
bendamustine
mantle cell lymphoma
busulfan
haematopoietic stem cell transplantation
carmustine
anaplastic astrocytoma
glioblastoma multiforme
mycosis fungoides
thrombosis
chlorambucil
lymphoma
waldenstrms macroglobulinaemia
chlormethine
cyclophosphamide
systemic lupus erythematosus
glomerulonephritis
granulomatosis with polyangiitis
dacarbazine
agranulocytosis
hepatic vein thrombosis
fotemustine
ifosfamide
lomustine
lurbinectedin
mechlorethamine
melphalan
haemopoietic stem cell transplant
streptozocin
carcinoid syndrome
hypoglycaemia
temozolomide
thiotepa
trabectedin
carboplatin
cisplatin
nedaplatin
oxaliplatin
bleomycin
squamous cell carcinoma
scleroderma
raynauds phenomenon
bortezomib
proteasome
dactinomycin
estramustine
ischaemic heart disease
ixabepilone
mitomycin
procarbazine
glioma
alemtuzumab
cd52
pancytopenia
bevacizumab
vegf
cetuximab
her1egfr
denosumab
rankl
giant cell tumour of bone
gemtuzumab ozogamicin
cd33
ibritumomab
cd20
90y
ipilimumab
ctla4
nivolumab
igg4
checkpoint inhibitor
inhibiting pd1
melanoma
lung cancer
malignant pleural mesothelioma
renal cell carcinoma
hodgkin lymphoma
urothelial carcinoma
colon cancer
esophageal squamous cell carcinoma
liver cancer
ofatumumab
panitumumab
pembrolizumab
pertuzumab
her2
rituximab
microscopic polyangiitis
tositumomab
i131
methaemoglobinaemia
hyperthyroidism
trastuzumab
afatinib
her4
aflibercept
axitinib
polycythaemia
bosutinib
bcrabl
pulmonary hypertension
crizotinib
dasatinib
ckit
epha2
pdgfr
erlotinib
gefitinib
imatinib
rhabdomyolysis
lapatinib
nilotinib
pazopanib
ckit
fgfr
vegfr
ponatinib
regorafenib
ruxolitinib
jak1
jak2
sorafenib
hepatocellular carcinoma
sunitinib
vandetanib
everolimus
temsirolimus
alitretinoin
retinoic acid receptor
retinoid x receptor
bexarotene
isotretinoin
acne
tamibarotene
differentiation syndrome
tretinoin
lenalidomide
il6
il2
pomalidomide
thalidomide
graft versus host disease
panobinostat
romidepsin
valproate
fragile x syndrome
familial adenomatous polyposis
hyperammonaemia
polycystic ovaries
vorinostat
anagrelide
phosphodiesterase 3
essential thrombocythaemia
arsenic trioxide
asparaginase
denileukin diftitox
acute kidney injury
vemurafenib
braf
isbn
goodman gilmans the pharmacological basis of therapeutics
issn
pmid
s2cid
l01
sps
m phase
microtubule
vinca alkaloids
taxanes
larotaxel
ortataxel
tesetaxel
epothilones
dna replication
antimetabolites
s phase
folic acid
dihydrofolate reductase inhibitor
aminopterin
thymidylate synthase inhibitor
purine
adenosine deaminase inhibitor
halogenated
ribonucleotide reductase inhibitor
rabacfosadine
thiopurine
pyrimidine
doxifluridine
gimeraciloteracil
dna polymerase inhibitor
cytarabine
hypomethylating agent
deoxyribonucleotide
topoisomerase inhibitors
camptotheca
belotecan
camptothecin
etirinotecan pegol
exatecan
lurtotecan
rubitecan
podophyllum
intercalation
anthracyclines
aclarubicin
amrubicin
pirarubicin
zorubicin
anthracenediones
losoxantrone
pixantrone
amsacrine
bisantrene
crisnatol
menogaril
crosslinking of dna
nonclassical
nitrogen mustards
trofosfamide
melphalan flufenamide
prednimustine
uramustine
nitrosoureas
semustine
nimustine
ranimustine
alkyl sulfonates
mannosulfan
treosulfan
aziridines
carboquone
triaziquone
triethylenemelamine
platinumbased
dicycloplatin
satraplatin
hydrazines
etoglucid
mitobronitol
pipobroman
triazenes
mitozolomide
streptomyces
mitomycins
plicamycin
photosensitizers
aminolevulinic acid
efaproxiral
methyl aminolevulinate
padeliporfin
porphyrin derivatives
porfimer sodium
talaporfin
temoporfin
verteporfin
enzyme inhibitors
tipifarnib
inhibitors
abemaciclib
alvocidib
palbociclib
ribociclib
seliciclib
carfilzomib
oprozomib
ixazomib
impdi
tiazofurin
masoprocol
parp inhibitor
fuzuloparib
niraparib
abiraterone acetate
olaparib
rucaparib
belinostat
entinostat
alpelisib
copanlisib
duvelisib
idelalisib
umbralisib
receptor antagonists
atrasentan
sex steroid
testolactone
adagrasib
asparagine depleters
pegaspargase
axicabtagene ciloleucel
belzutifan
brexucabtagene autoleucel
celecoxib
ciltacabtagene autoleucel
demecolcine
eflornithine
elesclomol
elsamitrucin
enasidenib
epacadostat
eribulin
estramustine
glasdegib
idecabtagene vicleucel
imetelstat
ivosidenib
lifileucel
lisocabtagene maraleucel
lonidamine
lucanthone
mitoguazone
mitotane
nadofaragene firadenovec
navitoclax
oblimersen
omacetaxine mepesuccinate
plitidepsin
tabelecleucel
retinoids
selinexor
sotorasib
tagraxofusp
talimogene laherparepvec
tazemetostat
tebentafusp
tiazofurine
tigilanol tiglate
tisagenlecleucel
veliparib
venetoclax
vorasidenib
vosaroxin
withdrawn
clinical trials
phase iii
targeted cancer therapy
monoclonal antibodies
receptor tyrosine kinase
erbb
her2neu
hyaluronidase
trastuzumab emtansine
trastuzumab deruxtecan
epcam
catumaxomab
edrecolomab
blood
lymphoid
glofitamab
elranatamab
mosunetuzumab
obinutuzumab
cd30
brentuximab
myeloid
amivantamab
atezolizumab
hyaluronidase
avelumab
axatilimab
belantamab mafodotin
bermekimab
blinatumomab
cemiplimab
daratumumab
dinutuximab beta
dostarlimab
durvalumab
elotuzumab
enfortumab vedotin
epcoritamab
inotuzumab ozogamicin
isatuximab
loncastuximab tesirine
mirvetuximab soravtansine
mogamulizumab
moxetumomab pasudotox
naxitamab
necitumumab
olaratumab
oportuzumab monatox
polatuzumab vedotin
ramucirumab
retifanlimab
sacituzumab govitecan
serplulimab
sugemalimab
tafasitamab
talquetamab
tarlatamab
teclistamab
tislelizumab
tisotumab vedotin
toripalimab
tremelimumab
tyrosine kinase inhibitors
aumolertinib
brigatinib
dacomitinib
icotinib
lazertinib
mobocertinib
olmutinib
osimertinib
rociletinib
neratinib
tucatinib
rtk class iii
ckit
avapritinib
masitinib
ripretinib
toceranib
flt3
lestaurtinib
gilteritinib
vegfr
cediranib
fruquintinib
lenvatinib
nintedanib
semaxanib
tivozanib
alectinib
ceritinib
entrectinib
futibatinib
infigratinib
larotrectinib
pemigatinib
pralsetinib
repotrectinib
selpercatinib
cmet
cabozantinib
capmatinib
nonreceptor
bcrabl
asciminib
radotinib
src
janus kinase
baricitinib
fedratinib
filgotinib
momelotinib
pacritinib
binimetinib
cobimetinib
selumetinib
trametinib
eml4
lorlatinib
brutons
acalabrutinib
ibrutinib
orelabrutinib
pirtobrutinib
zanubrutinib
fusion protein
proapoptotic
anxa2
prohibitin
adipotide
exotoxin
mtor inhibitors
ridaforolimus
hedgehog
sonidegib
vismodegib
cdk inhibitors
dalpiciclib
trilaciclib
kras
pi3k inhibitors
parsaclisib
erdafitinib
midostaurin
odronextamab
pexidartinib
quizartinib
tepotinib
respiratory system
oncology
benign tumors
hyperplasia
cyst
pseudocyst
hamartoma
dysplasia
carcinoma in situ
metastasis
primary tumor
sentinel lymph node
oral
oropharyngeal
laryngeal
nasopharyngeal
digestive system
bone
skin
urogenital
nervous system
endocrine system
carcinoma
sarcoma
blastoma
papilloma
adenoma
precancerous condition
paraneoplastic syndrome
staging
grading
ann arbor
prostate cancer staging
gleason grading system
dukes classification
carcinogenesis
cancer cell
carcinogen
tumor suppressor genes
oncogenes
clonally transmissible cancer
oncovirus
carcinogenic bacteria
research
index of oncology articles
history
cancer pain
cancer and nausea
diet
|
Links to external pages
Outloing links
www.wikidata.org
www.archive.org
www.medicinescomplete.com
www.doi.org
www.doi.org
search.worldcat.org
pubmed.ncbi.nlm.nih.gov
api.semanticscholar.org
www.doi.org
search.worldcat.org
pubmed.ncbi.nlm.nih.gov
www.doi.org
pubmed.ncbi.nlm.nih.gov
www.doi.org
search.worldcat.org
pubmed.ncbi.nlm.nih.gov
api.semanticscholar.org
www.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov
search.worldcat.org
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
reference.medscape.com
pubmed.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
www.medscape.org
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
reference.medscape.com
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
reference.medscape.com
foundation.wikimedia.org
foundation.wikimedia.org
www.wikimediafoundation.org
SEO Advice for en.wikipedia.org
In this section we provide pointers on how you can to optimize your web page so it can be found more easily by search engines and how to make it rank higher by optimizing the content of the page itself. For each of the individual criteria the maximum score is 100%. A score below 70% is considered to be indication that the page is not complying with general SEO standards and should be evaluated and/or fixed. Not every factor is weighted the same and some are not as important as others. Relatively unimportant factors like meta keywords are not included in the overall score.
Item | Factor | Pointers | |
---|---|---|---|
PageTitle | 100% | Far too many sites lack a page title. A page title is the first thing that shows in the search results so always use the title element. | |
Title relevance | 0% | A title should reflect the contents of a site. This site has a 0 % match | |
Title Length | 100% | Limit your title to anywhere between 40 and 70 characters. Your title was 42 characters long | |
Meta Description | 0% | A meta description is the second element that shows in the search results so always use the meta description. | |
Meta description length | 0% | The meta description should be between 145 and 160 characters. This meta description is 1 characters long. | |
Meta description relevance | 0% | Meta Description should reflect the contents of a site. This site has a 0 % match | |
Number of internal links | 30% | Linking to internal pages makes pages easier to find for search engines. Try to keep the number of links on your page roughly below 100. There are 1047 internal links on this page. | |
Folder structure | 100% | We found a folder structure in the links on your page. A good folder structure makes a site easier to navigate. We found 3 level 1 folders and 12 folders above or in the first level of navigation. | |
Headings | 0% | Headers should reflect the contents of a site. This site has a 0 % match | |
Links | 6% | Link anchors should to some degree reflect the contents of a site. This site has a 3 % match | |
Image alt tags | 0% | Image alt tags should to some degree reflect the contents of a site. This site has a 0 % match | |
Bold and italic | 9% | Bold and italic tags should reflect the contents of a site to some degree. This site has a 3 % match | |
Html ratio | 75% | Try to keep the html / text ratio as low as possible. More html means longer loading times. Layout should be handled in a serpate css file | |
Image descriptions | 57% | 57.142857142857 % of all images have been described via the "alt" attribute. Describing images with relevant text may lead to better results in the search engines. | |
Page errors | 100% | Pages with no errors display significantly faster on most browsers. We detected 0 errors and warnings | |
WordCount | 20% | An ideal page contains between 400 and 600 words.This page contains 5917 words | |
Server response time | 30% | A slow server slows down a website. This server responds 20.3% slower the average | |
Gzip compression | 30% | This site does not use Gzip compression. Pages may not display as fast as they could | |
Keywords in Domainname | 30% | There are no important keywords in your domain name | |
Keywords in domain path | 20% | There are no important keywords in the domain path | |
Structured Data | 100% | Structured data makes it easier for search engines to index your website | |
Inline css | 0% | Do not use inline css declarations. Inline css will slow down the rendering of the website. We detected 151 inline style declarations ( <a style="color:green">) with a size of 2447 bytes | |
Excessive use of the same words | 100% | There is no indication that there are one or more keywords that are used excessively. | |
Frames or iframes | 100% | Perfect, detected not (i)frames on your webpagina | |
Flash | 100% | Perfect, we detected no flash objects on your page | |
Css | 30% | We detected too much (2) CSS files on your page. Css files block the loading of a webpage. | |
Javascript | 100% | Perfect, we did not detect too many blocking JavaScript files | |
Mobile Website | 100% | Perfect, we found a responsive design for mobile users | |
Most important heading | 100% | Perfect, we detected a correct use of the most important (h1) heading! | |
Normalized headings | 40% | We dit not font a normalized heading structure. A heading 2 (h2) for example should be followed by a heading of an equal level (h2), a child heading (h3) or even a aprent heading (h1). |
How would you like to have SEO advice for all your pages ?? Start your SEO Dashboard and optimize your website!
en.wikipedia.org images and descriptions
7 images found at en.wikipedia.org Images can improve the user experience for a website by making a pag visually appealing Images can also add extra keyword relevance to a webpage by using alt tags. Images can also slow down a website. If the width and height for a picture is not specified for a browser know in advance how large the image is. A browser must first load the picture and see before it knows how much space should be on the page. Upon reservation In the meantime, the browser can do little but wait. When the height and width for the plate are given in the HTML code, a browser just continues to build for a page while the images load in the background.
http://en.wikipedia.org/static/images/icons/wikipedia.png height: 50 width: 50 description: no alt description found |
|
http://en.wikipedia.org/static/images/mobile/copyright/wikipedia-wordmark-en.svg height: height attribute not set width: width attribute not set description: wikipedia |
|
http://en.wikipedia.org/static/images/mobile/copyright/wikipedia-tagline-en.svg height: 13 width: 117 description: the free encyclopedia |
|
https://upload.wikimedia.org/wikipedia/commons/thumb/b/bd/ambox_current_red_asia_australia.svg/42px-ambox_current_red_asia_australia.svg.png height: 34 width: 42 description: no alt description found |
|
https://login.wikimedia.org/wiki/special:centralautologin/start?type=1x1 height: 1 width: 1 description: no alt description found |
|
http://en.wikipedia.org/static/images/footer/wikimedia-button.svg height: 29 width: 84 description: wikimedia foundation |
|
http://en.wikipedia.org/w/resources/assets/poweredby_mediawiki.svg height: 31 width: 88 description: powered by mediawiki |
How are images contributing to your SEO site-wise ? Your leading content tool has the awnsers!